Literature DB >> 16551254

Multiplexed protein array platforms for analysis of autoimmune diseases.

Imelda Balboni1, Steven M Chan, Michael Kattah, Jessica D Tenenbaum, Atul J Butte, Paul J Utz.   

Abstract

Several proteomics platforms have emerged in the past decade that show great promise for filling in the many gaps that remain from earlier studies of the genome and from the sequencing of the human genome itself. This review describes applications of proteomics technologies to the study of autoimmune diseases. We focus largely on biased technology platforms that are capable of analyzing a large panel of known analytes, as opposed to techniques such as two-dimensional gel electrophoresis (2DIGE) or mass spectroscopy that represent unbiased approaches (as reviewed in 1). At present, the main analytes that can be systematically studied in autoimmunity include autoantibodies, cytokines and chemokines, components of signaling pathways, and cell-surface receptors. We review the most commonly used platforms for such studies, citing important discoveries and limitations that exist. We conclude by reviewing advances in biomedical informatics that will eventually allow the human proteome to be deciphered.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16551254     DOI: 10.1146/annurev.immunol.24.021605.090709

Source DB:  PubMed          Journal:  Annu Rev Immunol        ISSN: 0732-0582            Impact factor:   28.527


  32 in total

1.  An entropic perspective of protein stability on surfaces.

Authors:  Thomas A Knotts; Nitin Rathore; Juan J de Pablo
Journal:  Biophys J       Date:  2008-03-07       Impact factor: 4.033

Review 2.  Gene-expression profiling in rheumatic disease: tools and therapeutic potential.

Authors:  Jason W Bauer; Hatice Bilgic; Emily C Baechler
Journal:  Nat Rev Rheumatol       Date:  2009-05       Impact factor: 20.543

Review 3.  Tumor-associated antigen arrays for the serological diagnosis of cancer.

Authors:  Carlos A Casiano; Melanie Mediavilla-Varela; Eng M Tan
Journal:  Mol Cell Proteomics       Date:  2006-05-29       Impact factor: 5.911

4.  The effects of tether placement on antibody stability on surfaces.

Authors:  Rebecca W Grawe; Thomas A Knotts
Journal:  J Chem Phys       Date:  2017-06-07       Impact factor: 3.488

5.  IRF9 and STAT1 are required for IgG autoantibody production and B cell expression of TLR7 in mice.

Authors:  Donna L Thibault; Alvina D Chu; Kareem L Graham; Imelda Balboni; Lowen Y Lee; Cassidy Kohlmoos; Angela Landrigan; John P Higgins; Robert Tibshirani; Paul J Utz
Journal:  J Clin Invest       Date:  2008-04       Impact factor: 14.808

6.  Peptide conformations for a microarray surface-tethered epitope of the tumor suppressor p53.

Authors:  Jun Feng; Ka-Yiu Wong; Gillian C Lynch; Xiaolian Gao; B Montgomery Pettitt
Journal:  J Phys Chem B       Date:  2007-11-16       Impact factor: 2.991

7.  Discovery of Phosphorylated Peripherin as a Major Humoral Autoantigen in Type 1 Diabetes Mellitus.

Authors:  Todd M Doran; Jumpei Morimoto; Scott Simanski; Eric J Koesema; Lorraine F Clark; Kevin Pels; Sydney L Stoops; Alberto Pugliese; Jay S Skyler; Thomas Kodadek
Journal:  Cell Chem Biol       Date:  2016-05-12       Impact factor: 8.116

Review 8.  Autoantibodies to tumor-associated antigens: reporters from the immune system.

Authors:  Eng M Tan; Jianying Zhang
Journal:  Immunol Rev       Date:  2008-04       Impact factor: 12.988

9.  Proteome profiling in murine models of multiple sclerosis: identification of stage specific markers and culprits for tissue damage.

Authors:  Ralf A Linker; Peter Brechlin; Sarah Jesse; Petra Steinacker; D H Lee; Abdul R Asif; Olaf Jahn; Hayrettin Tumani; Ralf Gold; Markus Otto
Journal:  PLoS One       Date:  2009-10-28       Impact factor: 3.240

10.  Type I interferon receptor controls B-cell expression of nucleic acid-sensing Toll-like receptors and autoantibody production in a murine model of lupus.

Authors:  Donna L Thibault; Kareem L Graham; Lowen Y Lee; Imelda Balboni; Paul J Hertzog; Paul J Utz
Journal:  Arthritis Res Ther       Date:  2009-07-22       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.